AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$CRL

Parisotto Shannon M sold $600K of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 2,039 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $294.12 ($0.60M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Aug 20, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The transaction is small relative to CRL's float and unlikely to affect market perception.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming regulatory or product developments not disclosed could influence insider behavior.

Relevance 4/10Novelty 4/10Timing: after‑market today

Background

Form 4 filings disclose insider trades; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

Officer Shannon M. Parisotto sold 2,039 shares for $599,710, reducing her stake to 4,807 shares via a 10b5‑1 plan.

Expected impact

No significant price impact expected.

Evidence & confidence

Sale size is modest relative to market cap and follows a pre‑arranged plan.

Market effects

Sector

None; insider sale does not affect the broader healthcare services sector.

Regional

None; limited to CRL shareholders.

Global

Low; isolated to a single micro‑cap insider transaction.

Counterpoint

What could challenge this read

The sale could be interpreted as a lack of confidence, but the 10b5‑1 plan suggests it is routine.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory services and products to the pharmaceutical and biotech industries.

  • Insider
    Shannon M. Parisotto

    Chief Executive Vice President, Discovery & Safety Assessment.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

AUG 21
$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

yahoo.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
AUG 14
$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

yahoo.com6 min
AUG 9
$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

simplywall.st6 min
AUG 7
$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.

simplywall.st6 min